The IL-36 Cytokine Rheostat: Hierarchical Regulation of Epithelial–Immune Crosstalk and Precision Therapy in Psoriatic and Related Dermatoses

Ze-Yun Qiao,1 Jing-Hua Liu,1 Na-Na Luo,2 Lei Tang,1 Wen-Yi Ma,1 Zi-Lin Cheng,1 Ping-Sheng Hao1,2 1Clinical Medical College, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People’s Republic of China; 2Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People’s Republic of ChinaCorrespondence: Ping-Sheng Hao, Hospital of Chengdu University of Traditional Chinese Medicine, No. 37, Twelve Bridges Road, Chengdu City, Sichuan Province, 610000, People’s Republic of China, Email [email protected]: The interleukin-36 (IL-36) cytokine subfamily—comprising IL-36α, IL-36β, IL-36γ, and their natural antagonists IL-36Ra and IL-38—has emerged as a central regulator of epithelial–immune communication and systemic inflammation. Acting through the IL-36 receptor complex (IL-1Rrp2/IL-1RAcP), IL-36 can be conceptualized as integrating protease-dependent molecular activation, multicellular amplification loops, and disease-specific network crosstalk within a unified hierarchical framework. At the molecular level, neutrophil-derived proteases license IL-36 activation, establishing a threshold that converts barrier stress into inflammatory signaling. Within cellular networks, keratinocyte-derived IL-36γ amplifies dendritic cell–Th17 interactions and neutrophil recruitment, while the antagonists IL-36Ra and IL-38 provide feedback restraint. Across the psoriatic spectrum, IL-36 acts as a driver cytokine in generalized pustular psoriasis (GPP), an amplifier in plaque psoriasis (PV), and a sustainer in psoriatic arthritis (PsA)—defining a gradient of cytokine dependency that is conceptually consistent with differential therapeutic responsiveness. Beyond psoriasis, IL-36 participates in neutrophilic, fibrosing, and atopic dermatoses, serving as a convergent inflammatory axis that bridges epithelial stress with systemic immune propagation. The successful clinical translation of IL-36R blockade—exemplified by spesolimab and imsidolimab—validates IL-36 as a tractable therapeutic target and underscores its role within the IL-17A/TNF-α/IL-23 cytokine network. Collectively, these advances position IL-36 as a cytokine rheostat capable of scaling immune intensity according to molecular and spatial context. Emerging multi-omic and spatial transcriptomic analyses are now redefining IL-36-high endotypes across inflammatory diseases, suggesting that IL-36 may serve as a reference axis for precision immunotherapy and as a conceptual model for hierarchical immune calibration in chronic inflammation.Keywords: IL-36, cytokine rheostat, protease activation, psoriatic disease, epithelial immunity, endotype-driven therapy, precision inflammation